Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573275 | 1.00 | EPHX2 (0.49) | EPHX2ALDH1A1MEN1KMT2AROCK2 | |
| SCHEMBL23573559 | 1.00 | EPHX2 (0.49) | EPHX2ALDH1A1MEN1KMT2AROCK2 | |
| SCHEMBL23573294 | 0.87 | EPHX2 (0.51) | EPHX2ALDH1A1MEN1KMT2AEPHX1 | |
| SCHEMBL18562931 | 0.81 | ROCK2 (0.44) | EPHX2ALDH1A1MEN1KMT2AROCK2 | |
| SCHEMBL18508520 | 0.81 | ROCK2 (0.44) | EPHX2ALDH1A1MEN1KMT2AROCK2 | |
| SCHEMBL16343831 | 0.81 | EPHX2 (0.72) | EPHX2 | |
| SCHEMBL19408793 | 0.80 | CA1 (0.46) | EPHX2ALDH1A1KMT2A | |
| SCHEMBL6539120 | 0.77 | EPHX2 (0.65) | EPHX2EPHX1 | |
| SCHEMBL3318469 | 0.77 | MEN1 (0.48) | EPHX2ALDH1A1MEN1KMT2AROCK2 | |
| SCHEMBL853826 | 0.76 | MEN1 (0.51) | EPHX2ALDH1A1MEN1KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | EPHX2 959/4885ALDH1A1 216/4885MEN1 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.